eli lilly trial retatrutide Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments A new clinical trial from
Description
Many patients begin to notice weight loss within the first 8 to 12 weeks of treatment
In addition, GLP-1R agonist therapy has a variety of dosing cycles, such as once-daily injections, twice-daily injections, and once-weekly injections, which was summarized in Table 1
It can also improve muscle mass
After eating, the hormone is released in the gut
You have complications including ruptures in the colon wall, fistulas, or other serious tissue damage
